Abeona Therapeutics Inc./$ABEO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Ticker
$ABEO
Sector
Primary listing
Employees
226
Headquarters
Website
ABEO Metrics
BasicAdvanced
$309m
5.38
$1.01
1.19
-
Price and volume
Market cap
$309m
Beta
1.19
52-week high
$7.54
52-week low
$4.00
Average daily volume
1.1m
Financial strength
Current ratio
6.93
Quick ratio
6.7
Long term debt to equity
7.463
Total debt to equity
15.682
Interest coverage (TTM)
-23.92%
Profitability
EBITDA (TTM)
-86.899
Gross margin (TTM)
-419.54%
Net profit margin (TTM)
1,223.08%
Operating margin (TTM)
-1,536.91%
Effective tax rate (TTM)
0.14%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-34.04%
Return on equity (TTM)
70.05%
Valuation
Price to earnings (TTM)
5.376
Price to revenue (TTM)
49.405
Price to book
1.88
Price to tangible book (TTM)
1.88
Price to free cash flow (TTM)
-3.411
Free cash flow yield (TTM)
-29.32%
Free cash flow per share (TTM)
-1.592
Growth
Earnings per share change (TTM)
-165.32%
3-year revenue growth (CAGR)
60.26%
10-year revenue growth (CAGR)
18.79%
3-year earnings per share growth (CAGR)
-43.26%
10-year earnings per share growth (CAGR)
-22.64%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abeona Therapeutics Inc. stock?
Abeona Therapeutics Inc. (ABEO) has a market cap of $309M as of May 04, 2026.
What is the P/E ratio for Abeona Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Abeona Therapeutics Inc. (ABEO) stock is 5.38 as of May 04, 2026.
Does Abeona Therapeutics Inc. stock pay dividends?
No, Abeona Therapeutics Inc. (ABEO) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Abeona Therapeutics Inc. dividend payment date?
Abeona Therapeutics Inc. (ABEO) stock does not pay dividends to its shareholders.
What is the beta indicator for Abeona Therapeutics Inc.?
Abeona Therapeutics Inc. (ABEO) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.